News & Articles
Selected Filters:
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve outpatient respiratory treatment
QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions
QIAGEN Digital Insights expands collaboration with Neo4j to advance biomedical data analysis
New agreement brings leaders in biomedical knowledge solutions and knowledge graph technologies together to aid the biopharmaceutical industry in analytics-driven drug discovery
QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer
QuantiFERON-TB Gold Plus remains crucial for the detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology
QIAcuityDx provides highly precise, absolute quantitation of target DNA and RNA, making it an ideal tool for monitoring cancer progression
New QIAstat-Dx IVD panel to identify patients at risk of developing Alzheimer’s disease
QIAGEN and Eli Lilly collaboration set to launch the first commercially available IVD Kit for APOE genotyping
QIAGEN NeuMoDx CT/NG Assay cleared by the FDA
NeuMoDx CT/NG Assay, designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the US
QIAGEN expands next-generation sequencing portfolio with QIAseq Normalizer Kits
Accelerating DNA library pooling for high-quality next-generation sequencing results
Danish National Genome Center selects QIAGEN for variant interpretation in oncology genome sequencing
QCI Interpret selected to support Denmark's whole-genome sequencing program
Enzymes for molecular biology
Discover enzymes and applications to catalyze your research success
QIAGEN’s liquid-based sample-prep-and-detection kit helps labs ramp up COVID testing capacity
The artus® SARS-CoV-2 Prep&Amp UM cuts PCR processing times by two thirds
QIAGEN launches CE-marked version of QuantiFERON® SARS-CoV-2 to assess T-cell response to COVID-19
The easy-to-use workflow can detect T-cell response early in the course of COVID-19 infection or following vaccination
QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529
The assays have shown efficacy against the newest variants of concern
QIAGEN announces the commercialization of the PreAnalytiX PAXgene Saliva Collector
Newly launched PAXgene Saliva Collector stabilizes collected sample to avoid preanalytical errors and thereby increases reproducibility and reliability of results
QIAGEN receives FDA authorization for rapid portable test that can analyze over 30 samples per hour for SARS-CoV-2 antigen
QIAreach SARS-CoV-2 Antigen Test, developed in collaboration with Ellume, provides accurate and objective results in 2 to 15 minutes
QIAGEN and GT Molecular collaborate to offer a complete SARS-CoV-2 wastewater detection solution
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
QIAGEN launches dedicated CRISPR products for rapid and simplified analysis of gene-editing experiments
Solutions combine liquid-based sample preparation with PCR detection and Sanger sequencing